Search results
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 2 days agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 6 days agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 7 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 6 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 7 days agoThe...endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment (NSAA) at one year after treatment.
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 5 days agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 6 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
MarionMade!: Running to help others who may not be able to walk
Gannett via AOL· 3 days agoLike one in 3,500 boys, Luke was diagnosed with Duchenne’s muscular dystrophy. The disease weakens...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 6 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 6 days agoThis development is seen as a positive for Sarepta's DMD treatment, Elevidys, which has demonstrated...